“Caring about a cause is important, but if you want to see change in the world, you need to take action.”
Dan is a recognized biotech/pharma leader and entrepreneur who brings more than 28 years of leadership experience to Mablytics. He has led commercialization efforts for multiple pharmaceutical brands and has extensive experience working on some of the industry’s largest oncology brands. Dan was the founder and president of The Patient Experience Project (PEP), which developed novel methodologies to ensure that patient populations were at the center of research, clinical trial development, and commercialization efforts. Dan successfully scaled PEP by working with numerous industry-leading brands before it was acquired in 2018 by JLL Partners and Water Street Healthcare Partners under the brand name EVERSANA. Before founding PEP, Dan spent 11 years at inVentiv Health in leadership roles, as well as at leading pharmaceutical and biotech companies, including DuPont Merck Pharmaceuticals and Exact Sciences. Dan has also led successful start-up ventures in communications, multimedia, and biotech, and he is experienced in mergers and acquisitions, financing, and other aspects of business development. Dan is active in philanthropy and serves on 3 not-for-profit boards focused on improving the lives of underserved communities. Dan holds an MBA from Canisius College and a B.S. in business administration from Le Moyne College.
Dan Bobear
Chief Executive Officer
“Caring about a cause is important, but if you want to see change in the world you need to take action.”
Dan is a recognized biotech/pharma leader and entrepreneur who brings over 28 years of leadership experience to Mablytics. He has led commercialization efforts for multiple pharmaceutical brands and has extensive experience working on some of the industry’s largest oncology brands. Dan was the Founder and President of The Patient Experience Project (PEP), which developed novel methodologies to ensure that patient populations were at the center of research, clinical trial development, and commercialization efforts. Dan successfully scaled PEP by working with numerous industry-leading brands before it was acquired in 2018 by Water Street and JLL Partners under the brand name EVERSANA. Before founding PEP, Dan spent eleven years at inVentiv Health in leadership roles, as well as at leading pharmaceutical and biotech companies including Dupont-Merck Pharmaceuticals and Exact Sciences. Dan has also led successful start-up ventures in communications, multimedia, and biotech, and he is experienced in mergers and acquisitions, financing, and other aspects of business development. Dan is active in philanthropy and serves on three not-for-profit boards focused on improving the lives of under-served communities. Dan holds an M.B.A. from Canisius College and a B.S. in Business Administration from Le Moyne College.
Rafael E. Bernal
Chief Operating Officer
“It's a privilege to be surrounded by so much talent and innovation. I’m excited to help guide the corporate health and progress of our company.”
Rafael served as the chief financial officer at the inception of Mablytics and assumed the role of chief operating officer in 2022. A Wall Street veteran with more than 20 years of experience working at top-tier firms such as BlackRock, AllianceBernstein, ICAP, and Tullett Prebon, Rafael’s primary focus is on administering to Mablytics’ financial health. He led the equity fundraising efforts for Mablytics in 2020, as well as convertible note fundraising in 2021, and he is a driver of daily and long-term strategic initiatives for the firm. Among his governance duties is the negotiation of agreements with Mablytics’ corporate and educational stakeholders. Rafael has degrees in accounting and finance from Baruch College and holds FINRA Series 7 and 63 licenses.
Chief Operating Officer
“It's a privilege to be surrounded by so much talent and innovation. I’m excited to help guide the corporate heath and progress of our company.”
Rafael served as the Chief Financial Officer at the inception of Mablytics and assumed the role of Chief Operating Officer in 2022. A Wall Street veteran with over twenty years of experience working at top-tier firms such as Blackrock, Alliance Bernstien, ICAP and Tullet Prebon, Rafael’s primary focus is on administering to Mablytics’ financial health. He led the equity fund-raising efforts for Mablytics in 2020 as well as convertible-note fundraising in 2021 and he is a driver of daily and long-term strategic initiatives for the firm. Among his governance duties is the negotiation of agreements with Mablytics’ corporate and educational stakeholders. Rafael has degrees in Accounting and in Finance (holds FINRA Series 7 and 63 Licenses) from Baruch College.
Eric Sjoberg, Ph. D
Chief Scientific Officer
“I never tire of the excitement of discovery – and the prospect of changing lives for the better.”
Dr. Sjoberg has more than 25 years of experience in biotechnology with expertise in pharmacology, biochemistry, molecular biology, and assay development. Prior to cofounding Mablytics, Dr. Sjoberg cofounded OrPhi Therapeutics, a pharmacological chaperone company focused on rare disease, where he served as vice president, preclinical development. Prior to OrPhi Therapeutics, he held positions of increasing responsibility including director, preclinical biology, at Amicus Therapeutics, where he helped establish a new lab focused on therapeutic protein discovery and production. He was also instrumental in leading the discovery efforts using pharmacological chaperones for 3 different preclinical programs. Dr. Sjoberg has published 17 peer-reviewed scientific articles, has been the principal investigator or co-investigator on 8 SBIR or private foundation grants, and is the inventor on 7 issued patents in the biochemistry field. Dr. Sjoberg received his B.S. and Ph.D. from the University of California, San Diego, and did his postdoctoral research at Cytel Corporation under the guidance of James Paulson.
Eric Sjoberg
Chief Scientific Officer
“I never tire of the excitement of discovery – and the prospect of changing lives for the better.”
Dr. Sjoberg has over 25 years of experience in biotechnology with expertise in pharmacology, biochemistry, molecular biology and assay development. Prior to co-founding Mablytics, Dr. Sjoberg co-founded OrPhi Therapeutics, a pharmacological chaperone company focused on rare disease, where he served as Vice President, Preclinical Development. Prior to OrPhi Therapeutics, he held positions of increasing responsibility including Director, Preclinical Biology, at Amicus Therapeutics, where he helped establish a new lab focused on therapeutic protein discovery and production. He was also instrumental in leading the discovery efforts using pharmacological chaperones for three different preclinical programs. Dr. Sjoberg has published seventeen peer-reviewed scientific articles, has been the Principal Investigator or Co-Investigator on eight SBIR or private foundation grants, and he is the inventor on seven issued patents in the biochemistry field. Dr. Sjoberg received his B.S. and Ph.D. from the University of California, San Diego and did his postdoctoral research at Scripps Research Institute under the guidance of James Paulson.
Anthony Stevens, Ph. D
Vice President of Research and Development
“My passion for scientific innovation and discovery makes it hard for me to call my job ‘work’—I love doing science.”
With more than 25 years of experience discovering and developing successful biotech solutions across multiple disease states, Dr. Stevens is well equipped to lead the R&D team at Mablytics. He has expertise in display technologies, proteomics, molecular biology, and assay development, as well in the development of monoclonal antibodies. Before leading the discovery and optimization of fully human monoclonal antibodies at Mablytics, Dr. Stevens was a cofounding scientist and VP of discovery at OrPhi Therapeutics, a principal investigator at Amicus Therapeutics, and cofounder and chief technology officer at Target Protein Technologies. Dr. Stevens has been awarded multiple SBIR and private institution grants and is an inventor on multiple patents. Dr. Stevens earned his B.S. in chemistry at the University of California, Riverside, his M.S. in analytical chemistry at the University of Arizona, and his Ph.D. in chemistry/biochemistry at the University of California, San Diego.
Anthony Stevens
VP of Research & Development
“My passion for scientific innovation and discovery makes it hard for me to call my job ‘work’—I love doing science.”
With over 25 years of experience discovering and developing successful biotech solutions across multiple disease states, Dr. Stevens is well equipped to lead the R&D team at Mablytics. He has expertise in display technologies, proteomics, molecular biology and assay development, as well in the development of monoclonal antibodies. Before leading the discovery and optimization of fully human monoclonal antibodies at Mablytics, Dr. Stevens was a co-founding scientist and VP of Discovery at OrPhi Therapeutics, a Principal Investigator at Amicus Therapeutics, and co-founder and Chief Technology Officer at Target Protein Technologies. Dr. Stevens has been awarded multiple SBIR and private institution grants and is an inventor on multiple patents. Dr. Stevens earned his B.S. in Chemistry at the University of California, Riverside, his M.S. in Analytical Chemistry at the University of Arizona, and his Ph.D. in Chemistry/Biochemistry at the University of California, San Diego.
Sundar Subramaniam
Founder and Board Member
“Meeting new—and completely unique—challenges every day brings breakthrough solutions that help us to live fuller lives.”
A founding member of Mablytics, Sundar has more than 30 years of experience leading the development of many successful tech and biotech companies, from both the technology and governance sides. His list of past and current endeavors is quite varied and extensive, and includes such accomplishments as holding directorial roles at smartShift, MedMinder, Intigua, and Knome to name just a few. Sundar was an original investor and CEO of Sialix/Siamab, where he was instrumental in directing company strategy, management, and fundraising, leading to a $202 million exit via acquisition in 2019. He is also a founder at IBCC, and chairman and CEO from 1988 to the present, as well as a chairman or CEO and founder of 5 companies that had IPOs, 2 of which were over $1 billion. Sundar has lectured at MIT and Harvard and is an adjunct assistant professor of finance at Brandeis University. Sundar received his B.S. in economics and computer science from Brandeis University, an MBA from MIT, and an M.S. from the Harvard-MIT Division of Health Sciences and Technology.
Sundar Subramaniam
Founder and Board Member
“Meeting new – and completely unique – challenges every day brings breakthrough solutions that help us to live fuller lives.”
A founding member of Mablytics, Sundar has over 30 years of experience leading the development of many successful tech and biotech companies, from both the technology and governance sides. His list of past and current endeavors is quite varied and extensive, and includes such accomplishments as holding Directorial roles at Smartshift, Medminder, Intigua and Knome to name just a few. Sundar was an original investor and CEO of Sialix/SiaMab, where he was instrumental in directing company strategy, management and fundraising, leading to a $202MM exit via acquisition in 2019. He is also a Founder at IBCC, and Chairman and CEO from 1988 to the present, as well as a Chairman or CEO and Founder of five companies that had IPOs, 2 of over $1B. Sundar has lectured at MIT and Harvard and is an Adjunct Assistant Professor of Finance at Brandeis University. Mr. Subramaniam received his Bachelor of Science in Economics and Computer Science from Brandeis University, an M.B.A. from MIT and an M.S. from the Harvard-MIT Division of Health Sciences and Technology.
